Decades of disciplined reinvesting built a balance that outpaces any reasonable spending plan, yet the dividends keep buying shares destined for no one. Three ETFs can reverse that engine before another compounding cycle slips by untouched.
Three low-cost ETFs have quietly made ordinary savers into millionaires, but choosing the wrong one for your risk tolerance could cost you years of compounding. The difference between them is smaller than the fund companies want you to think, and bigger than most investors reali…
One rival semiconductor ETF has quietly lapped the most popular chip fund on the market over the past year, and the reason comes down to a single position that most investors never think to question.
Mortgage rates just crossed 7% for the first time in this cycle, with the 30-year fixed at 7.03%. Housing affordability and every rate-sensitive builder, lender and REIT feel this immediately.
Source: FRED · MORTGAGE30USAmendment No. 2 holds the proposed $120 million NYSE deal in place
A second amendment to the S-1 keeps PBT Land & Minerals on track for a $120 million NYSE listing, putting a pure oil and gas mineral rights owner in front of public investors at a moment when royalty assets are consolidating fast. Terms are still being refined, so pricing is the next milestone to watch.
Source: SEC filingCity Therapeutics files for Nasdaq IPO with a four-bank syndicate led by Goldman Sachs
City Therapeutics has filed its S-1 to list on Nasdaq, with Goldman Sachs, Jefferies, Stifel and Oppenheimer running the books. Terms and deal size are not set yet, so the price range in the first amendment is the number that will define this one.
Source: SEC filingNYLIM MacKay's new high-income muni fund undercuts today's other launch by a wide margin at 0.34% net, versus 0.99% for Logan Capital's international equity ETF. Cheap tax-exempt yield keeps drawing issuers into an already crowded muni shelf.
Comparable sales rose 9.4% and digital comps jumped 19.5%, a pace that looks nothing like the pullback Kroger just flagged. One catch for anyone doing the math on the earnings beat: $0.15 a share came from non-recurring IEEPA tariff refunds.
Arm's 8.5% slide was the deepest move in a 111-stock priority list at Wednesday's close, with Bruker leading the upside at 7.5%.
The S&P 500 held its ground by less than a point while the Dow gave back 148, a split that says the bid is still parked in a narrow slice of the market. Track breadth here.
Musk is signing off on Grok living inside XChat group threads, pushing xAI from a standalone chatbot toward a default feature of X's messaging layer and squarely at OpenAI's consumer turf.
RT @XFreeze: Grok is now being tested inside XChat group chats...and soon it’ll respond just like another person You can just tag @Grok an…
A 9.6% intraday jump adds close to a billion dollars of market value to a $9.9 billion company in a single session. Moves this size are rare for a life sciences tools name, so watch whether the gain holds into the close.
